CB1 cannabinoid receptor deficiency promotes cardiac remodeling induced by pressure overload in mice

International Journal of Cardiology

Volumn 167, Issue 5, 2013, Pages 1936-1944

  Liao, Yulin ^a   Bin, Jianping ^a   Luo, Tao ^a   Zhao, Hui ^b   Ledent, Catherine ^d   Asakura, Masanori ^b   Xu, Dingli ^a   Takashima, Seiji ^c   Kitakaze, Masafumi ^a,b  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

^c OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

Author keywords

Cannabinoid receptors; Cardiac remodeling; Epidermal growth factor receptor; Heart failure; Mitogen activated protein kinases

Indexed keywords

ADENYLATE CYCLASE; CANNABINOID 1 RECEPTOR; CANNABINOID 1 RECEPTOR AGONIST; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR; FORSKOLIN; ISOPRENALINE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARDIAC REMODELING; CARDIOVASCULAR EFFECT; CARDIOVASCULAR MORTALITY; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME ACTIVATION; HEART DISEASE; HEART FAILURE; HEART HEMODYNAMICS; HEART LEFT VENTRICLE CONTRACTILITY; HEART LEFT VENTRICLE DP-DT; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART LEFT VENTRICLE OVERLOAD; HEART LEFT VENTRICLE PRESSURE; HEART MUSCLE CELL; HEART VENTRICLE HYPERTROPHY; LARGE HEART WEIGHT TO BODY WEIGHT RATIO; LUNG CONGESTION; LUNG WEIGHT TO BODY WEIGHT RATIO; MEDICAL PARAMETERS; MOLECULAR PATHOLOGY; MOUSE; NEWBORN; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; RAT; SIGNAL TRANSDUCTION; WILD TYPE;

CANNABINOID RECEPTORS; CARDIAC REMODELING; EPIDERMAL GROWTH FACTOR RECEPTOR; HEART FAILURE; MITOGEN-ACTIVATED PROTEIN KINASES;

ANIMALS; ANIMALS, NEWBORN; CELLS, CULTURED; HEART FAILURE; MALE; MICE; MICE, INBRED ICR; MICE, KNOCKOUT; PHOSPHORYLATION; RATS; RECEPTOR, CANNABINOID, CB1; RECEPTOR, EPIDERMAL GROWTH FACTOR; VENTRICULAR REMODELING;

EID: 84883286170     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2012.05.033     Document Type: Article

References (49)

1. R. Sarzani Endocannabinoids, blood pressure and the human heart J Neuroendocrinol 20 Suppl. 1 2008 58 62
2. F. Weis, A. Beiras-Fernandez, and R. Sodian Substantially altered expression pattern of cannabinoid receptor 2 and activated endocannabinoid system in patients with severe heart failure J Mol Cell Cardiol 48 2010 1187 1193
3. S. Batkai, P. Pacher, and D. Osei-Hyiaman Endocannabinoids acting at cannabinoid-1 receptors regulate cardiovascular function in hypertension Circulation 110 2004 1996 2002
4. N. Niederhoffer, K. Schmid, and B. Szabo The peripheral sympathetic nervous system is the major target of cannabinoids in eliciting cardiovascular depression Naunyn Schmiedebergs Arch Pharmacol 367 2003 434 443
5. B. Kola, E. Hubina, and S.A. Tucci Cannabinoids and ghrelin have both central and peripheral metabolic and cardiac effects via AMP-activated protein kinase J Biol Chem 280 2005 25196 25201
6. J.A. Wagner, M. Abesser, J. Karcher, M. Laser, and G. Kunos Coronary vasodilator effects of endogenous cannabinoids in vasopressin-preconstricted unpaced rat isolated hearts J Cardiovasc Pharmacol 46 2005 348 355
7. M. Packer, M.R. Bristow, and J.N. Cohn The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group N Engl J Med 334 1996 1349 1355
8. M. Packer, A.J. Coats, and M.B. Fowler Effect of carvedilol on survival in severe chronic heart failure N Engl J Med 344 2001 1651 1658
9. G. Kunos, Z. Jarai, and S. Batkai Endocannabinoids as cardiovascular modulators Chem Phys Lipids 108 2000 159 168
10. C.R. Hiley Endocannabinoids and the heart J Cardiovasc Pharmacol 53 2009 267 276
11. A. Samat, B. Tomlinson, S. Taheri, and G.N. Thomas Rimonabant for the treatment of obesity Recent Pat Cardiovasc Drug Discov 3 2008 187 193
12. S. Batkai, P. Mukhopadhyay, J. Harvey-White, R. Kechrid, P. Pacher, and G. Kunos Endocannabinoids acting at CB1 receptors mediate the cardiac contractile dysfunction in vivo in cirrhotic rats Am J Physiol Heart Circ Physiol 293 2007 H1689 H1695
13. P. Mukhopadhyay, S. Batkai, and M. Rajesh Pharmacological inhibition of CB1 cannabinoid receptor protects against doxorubicin-induced cardiotoxicity J Am Coll Cardiol 50 2007 528 536
14. P. Mukhopadhyay, B. Horvath, and M. Rajesh Fatty acid amide hydrolase is a key regulator of endocannabinoid-induced myocardial tissue injury Free Radic Biol Med 50 2011 179 195
15. E.J. Topol, M.G. Bousser, and K.A. Fox Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial Lancet 376 2010 517 523
16. Y. Liao, J. Bin, and M. Asakura Deficiency of type 1 cannabinoid receptors worsens acute heart failure induced by pressure overload in mice Eur Heart J 33 24 2012 3124 3133
17. C. Ledent, O. Valverde, and G. Cossu Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice Science 283 1999 401 404
18. Y. Liao, F. Ishikura, and S. Beppu Echocardiographic assessment of LV hypertrophy and function in aortic-banded mice: necropsy validation Am J Physiol Heart Circ Physiol 282 2002 H1703 H1708
19. C.J. Barrick, M. Yu, H.H. Chao, and D.W. Threadgill Chronic pharmacologic inhibition of EGFR leads to cardiac dysfunction in C57BL/6J mice Toxicol Appl Pharmacol 228 2008 315 325
20. M. Asakura, M. Kitakaze, and S. Takashima Cardiac hypertrophy is inhibited by antagonism of ADAM12 processing of HB-EGF: metalloproteinase inhibitors as a new therapy Nat Med 8 2002 35 40
21. I. Gobel, A.U. Trendelenburg, S.L. Cox, A. Meyer, and K. Starke Electrically evoked release of [(3)H]noradrenaline from mouse cultured sympathetic neurons: release-modulating heteroreceptors J Neurochem 75 2000 2087 2094
22. S. Sagan, L. Venance, Y. Torrens, J. Cordier, J. Glowinski, and C. Giaume Anandamide and WIN 55212-2 inhibit cyclic AMP formation through G-protein-coupled receptors distinct from CB1 cannabinoid receptors in cultured astrocytes Eur J Neurosci 11 1999 691 699
23. J.R. Privratsky, L.E. Wold, J.R. Sowers, M.T. Quinn, and J. Ren AT1 blockade prevents glucose-induced cardiac dysfunction in ventricular myocytes: role of the AT1 receptor and NADPH oxidase Hypertension 42 2003 206 212
24. Y. Shintani, S. Takashima, and Y. Asano Glycosaminoglycan modification of neuropilin-1 modulates VEGFR2 signaling EMBO J 25 2006 3045 3055
25. Y. Liao, M. Asakura, and S. Takashima Benidipine, a long-acting calcium channel blocker, inhibits cardiac remodeling in pressure-overloaded mice Cardiovasc Res 65 2005 879 888
26. E. Fride The endocannabinoid-CB(1) receptor system in pre- and postnatal life Eur J Pharmacol 500 2004 289 297
27. Y. Liao, M. Asakura, and S. Takashima Celiprolol, a vasodilatory beta-blocker, inhibits pressure overload-induced cardiac hypertrophy and prevents the transition to heart failure via nitric oxide-dependent mechanisms in mice Circulation 110 2004 692 699
28. 1 receptor attenuates cardiac hypertrophy and prevents heart failure in murine left ventricular pressure-overload model Circ Res 93 2003 759 766
29. M.C. Shibata, M.D. Flather, and D. Wang Systematic review of the impact of beta blockers on mortality and hospital admissions in heart failure Eur J Heart Fail 3 2001 351 357
30. 2B receptors begun after myocardial infarction prevents cardiac remodeling in rats Circulation 114 2006 1923 1932
31. J. Kim, A. Ogai, and S. Nakatani Impact of blockade of histamine H2 receptors on chronic heart failure revealed by retrospective and prospective randomized studies J Am Coll Cardiol 48 2006 1378 1384
32. K. Evaul, and S.R. Hammes Cross-talk between G protein-coupled and epidermal growth factor receptors regulates gonadotropin-mediated steroidogenesis in Leydig cells J Biol Chem 283 2008 27525 27533
33. C.K. Yeh, P.M. Ghosh, and H. Dang beta-Adrenergic-responsive activation of extracellular signal-regulated protein kinases in salivary cells: role of epidermal growth factor receptor and cAMP Am J Physiol Cell Physiol 288 2005 C1357 C1366
34. S. Okumura, G. Takagi, and J. Kawabe Disruption of type 5 adenylyl cyclase gene preserves cardiac function against pressure overload Proc Natl Acad Sci U S A 100 2003 9986 9990
35. L. Yan, D.E. Vatner, and J.P. O'Connor Type 5 adenylyl cyclase disruption increases longevity and protects against stress Cell 130 2007 247 258
36. S. Okumura, D.E. Vatner, and R. Kurotani Disruption of type 5 adenylyl cyclase enhances desensitization of cyclic adenosine monophosphate signal and increases Akt signal with chronic catecholamine stress Circulation 116 2007 1776 1783
37. W.G. Thomas, Y. Brandenburger, D.J. Autelitano, T. Pham, H. Qian, and R.D. Hannan Adenoviral-directed expression of the type 1A angiotensin receptor promotes cardiomyocyte hypertrophy via transactivation of the epidermal growth factor receptor Circ Res 90 2002 135 142
38. S. Kagiyama, S. Eguchi, G.D. Frank, T. Inagami, Y.C. Zhang, and M.I. Phillips Angiotensin II-induced cardiac hypertrophy and hypertension are attenuated by epidermal growth factor receptor antisense Circulation 106 2002 909 912
39. P.A. Lucchesi, A. Sabri, S. Belmadani, and K. Matrougui Involvement of metalloproteinases 2/9 in epidermal growth factor receptor transactivation in pressure-induced myogenic tone in mouse mesenteric resistance arteries Circulation 110 2004 3587 3593
40. H. Zhang, D. Chalothorn, L.F. Jackson, D.C. Lee, and J.E. Faber Transactivation of epidermal growth factor receptor mediates catecholamine-induced growth of vascular smooth muscle Circ Res 95 2004 989 997
41. Y. Kawasaki, T. Kohno, and R.R. Ji Different effects of opioid and cannabinoid receptor agonists on C-fiber-induced extracellular signal-regulated kinase activation in dorsal horn neurons in normal and spinal nerve-ligated rats J Pharmacol Exp Ther 316 2006 601 607
42. M.L. Casanova, C. Blazquez, and J. Martinez-Palacio Inhibition of skin tumor growth and angiogenesis in vivo by activation of cannabinoid receptors J Clin Invest 111 2003 43 50
43. A. Ellert-Miklaszewska, B. Kaminska, and L. Konarska Cannabinoids down-regulate PI3K/Akt and Erk signalling pathways and activate proapoptotic function of Bad protein Cell Signal 17 2005 25 37
44. M.S. Alkaitis, C. Solorzano, R.P. Landry, D. Piomelli, J.A. DeLeo, and E.A. Romero-Sandoval Evidence for a role of endocannabinoids, astrocytes and p38 phosphorylation in the resolution of postoperative pain PLoS One 5 2010 e10891
45. J. Liu, B. Gao, and F. Mirshahi Functional CB1 cannabinoid receptors in human vascular endothelial cells Biochem J 346 Pt 3 2000 835 840
46. M. Rajesh, P. Mukhopadhyay, G. Hasko, L. Liaudet, K. Mackie, and P. Pacher Cannabinoid-1 receptor activation induces reactive oxygen species-dependent and -independent mitogen-activated protein kinase activation and cell death in human coronary artery endothelial cells Br J Pharmacol 160 2010 688 700
47. P. Mukhopadhyay, M. Rajesh, and S. Batkai CB1 cannabinoid receptors promote oxidative stress and cell death in murine models of doxorubicin-induced cardiomyopathy and in human cardiomyocytes Cardiovasc Res 85 2010 773 784
48. S.E. Nissen, S.J. Nicholls, and K. Wolski Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial JAMA 299 2008 1547 1560
49. A. Quercioli, Z. Pataky, and G. Vincenti Elevated endocannabinoid plasma levels are associated with coronary circulatory dysfunction in obesity Eur Heart J 32 2011 1369 1378